Home › Sudden Cardiac Arrest › NCT06455514

Post-CA Neuroprotection With Magnesium

Neuroprotection Following Cardiac Arrest: A Randomized Control Trial of Magnesium

Who can join

Ages 18 to 85 · All sexes

Inclusion Criteria:

* Documented post-cardiac arrest patient with Return of Spontaneous Circulation (ROSC) achieved \<2 hours prior to recruitment

Exclusion Criteria:

* Age \< 18 years or \> 85 years
* Traumatic cardiac arrests
* Unsustained ROSC (\<20 minutes)
* Patient who is responsive/able to follow motor commands within 1 hour of achieving ROSC
* Plan for withdrawal of life support within 72 hours of ROSC
* Known pregnant women at the time of the cardiac arrest
* Known prisoners at the time of the cardiac arrest
* Subjects who have a medical o social condition that would make them inappropriate for the study based on the PI's or clinical team judgement.

About the study

The purpose of this pilot interventional study is to collect preliminary data on administering magnesium sulfate as a neuroprotective medication in patients who achieved Return of Spontaneous Circulation (ROSC) following Cardiac Arrest (CA). The primary aims are to assess the feasibility and safety of administering magnesium and measure serum markers of neuronal injury at prespecified time points in the post-cardiac arrest period. Because this is a pilot study with a limited sample size, the primary objective is to evaluate the precision and stability of the collected measures to inform the design and formal analysis in a larger trial.

What is being tested

• Magnesium Sulfate (drug)
• Saline (drug)

Sponsor: NYU Langone Health · Participants: 178 · Started: Mar 25, 2025

Contact the study team

• Anelly Gonzales · Phone: 646-501-6923
• Natalia Leontovich · Phone: 646-501-6923

Official record on ClinicalTrials.gov — NCT06455514

Locations in the U.S.

Conditions

• Sudden Cardiac Arrest

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.